Política de cookies

Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso.

Más información
Permissions Requests - Help - - Sign up - Phone number 902 888 740

2017 FI

© Thomson Reuters, Journal Citation Reports, 2017

Indexed in:

Index Medicus/Medline, Excerpta Medica/EMBASE, IBECS, IME Cancerlit, Bibliomed, CabHealth, Scisearch, HealthStar, Scopus, Prous, Science Intergews, Science Citation Index Expanded.


  • Impact Factor: 1.644 (2017)
  • CiteScore 2017: 1.24
    Read more
  • SCImago Journal Rank (SJR):0,504
  • Source Normalized Impact per Paper (SNIP):0,791

© Clarivate Analytics, Journal Citation Reports 2017

Allergol Immunopathol (Madr) 2016;44:106-12 - DOI: 10.1016/j.aller.2015.01.011
Original Article
Effect of once-daily generic ciclesonide on exhaled nitric oxide in atopic children with persistent asthma
J. Mallola,, , V. Aguirrea, A. Gallardoa, E. Corteza, C. Sáncheza, C. Riquelmea, P. Córdovaa, M. Martíneza, A. Galindob
a Department of Paediatric Respiratory Medicine, Hospital CRS El Pino, University of Santiago de Chile (USACH), Chile
b Respiratory Physiotherapist, “El Manzano” Primary Health Care Centre, Santiago, Chile
Received 05 November 2014, Accepted 31 January 2015

Ciclesonide (CIC) is an effective inhaled corticosteroid for treating asthmatic children. However, its effect on airway inflammation assessed by the fraction of exhaled nitric oxide (FENO) in children with persistent asthma is virtually unknown. We aimed to assess the effect of once-daily generic CIC, 80 or 160μg, on FENO, lung function, asthma control and bronchial hyperresponsiveness, in atopic children with persistent asthma.


This was a 12-week, randomised, double-blind, parallel-group study. Sixty children with mild-to-moderate persistent asthma were recruited. Changes in FENO, asthma control score, lung function (FEV1) and bronchial hyperresponsiveness to methacholine (BHR) were used to assess the effects of both CIC doses. Non-normally distributed variables were log-transformed to approximate normality, and parametric tests were used for comparisons within and between groups at baseline and after 12 weeks of treatment.


In the CIC 80μg group, FENO decreased from 45.0ppb (95% CI 37.8–53.7) to 32.7ppb (95% CI 21.0–47.3) at the end of study (P=0.021), whereas in the CIC 160μg group, FENO decreased from 47.3ppb (95% CI 40.4–55.3) to 30.5ppb (95% CI 24.1–38.7) (P<0.001). The difference between groups in FENO at the end of study was not significant (P=0.693). There was a significant improvement of asthma control with both CIC doses but there was no significant change in BHR or FEV1 in either group.


Once-daily generic ciclesonide (80μg or 160μg), for 12 weeks, is effective to improve airway inflammation and asthma control in atopic children with persistent asthma.

Airway inflammation, Asthma control, Disease management, Inhaled corticosteroids, FENO, Paediatrics
Download PDF


Read the complete contents of this article

Already registered?